Bioimpact Capital LLC decreased its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) by 1.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 446,457 shares of the company’s stock after selling 6,513 shares during the quarter. Y-mAbs Therapeutics makes up approximately 1.3% of Bioimpact Capital LLC’s holdings, making the stock its 19th largest holding. Bioimpact Capital LLC owned 1.02% of Y-mAbs Therapeutics worth $7,237,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently modified their holdings of the company. BlackRock Inc. lifted its position in Y-mAbs Therapeutics by 1.2% during the 3rd quarter. BlackRock Inc. now owns 2,736,860 shares of the company’s stock worth $78,110,000 after acquiring an additional 33,169 shares in the last quarter. Russell Investments Group Ltd. lifted its position in Y-mAbs Therapeutics by 1,119.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 36,280 shares of the company’s stock worth $1,035,000 after acquiring an additional 33,304 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Y-mAbs Therapeutics by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 577,111 shares of the company’s stock valued at $16,470,000 after purchasing an additional 26,064 shares in the last quarter. Brandywine Global Investment Management LLC acquired a new position in shares of Y-mAbs Therapeutics in the 3rd quarter valued at approximately $929,000. Finally, Alliancebernstein L.P. raised its position in shares of Y-mAbs Therapeutics by 5.1% in the 3rd quarter. Alliancebernstein L.P. now owns 1,417,809 shares of the company’s stock valued at $40,464,000 after purchasing an additional 69,213 shares in the last quarter. Institutional investors and hedge funds own 60.50% of the company’s stock.
YMAB traded up $0.51 during trading on Tuesday, reaching $10.29. 387,745 shares of the company were exchanged, compared to its average volume of 689,809. The stock has a market cap of $449.82 million, a P/E ratio of -3.81 and a beta of 1.48. The firm has a 50 day moving average of $11.08 and a 200 day moving average of $13.12. Y-mAbs Therapeutics, Inc. has a 52 week low of $6.50 and a 52 week high of $39.82.
A number of equities analysts have issued reports on YMAB shares. Wedbush cut their target price on Y-mAbs Therapeutics from $28.00 to $21.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 10th. Guggenheim started coverage on Y-mAbs Therapeutics in a research report on Thursday, February 3rd. They issued a “buy” rating and a $22.00 target price on the stock. Zacks Investment Research raised Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $63.00 target price on shares of Y-mAbs Therapeutics in a research report on Friday, April 29th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Y-mAbs Therapeutics has an average rating of “Buy” and a consensus target price of $31.60.
In other news, CFO Bo Kruse sold 4,000 shares of the stock in a transaction on Tuesday, February 22nd. The stock was sold at an average price of $7.85, for a total value of $31,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 27.28% of the stock is owned by corporate insiders.
Y-mAbs Therapeutics Profile (Get Rating)
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.
- Get a free copy of the StockNews.com research report on Y-mAbs Therapeutics (YMAB)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
- Beware The Rebound In Home Depot
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.